JP2021535147A5 - - Google Patents
Info
- Publication number
- JP2021535147A5 JP2021535147A5 JP2021510761A JP2021510761A JP2021535147A5 JP 2021535147 A5 JP2021535147 A5 JP 2021535147A5 JP 2021510761 A JP2021510761 A JP 2021510761A JP 2021510761 A JP2021510761 A JP 2021510761A JP 2021535147 A5 JP2021535147 A5 JP 2021535147A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- composition
- acceptable salt
- teeth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725941P | 2018-08-31 | 2018-08-31 | |
| US62/725,941 | 2018-08-31 | ||
| PCT/US2019/049195 WO2020047496A1 (en) | 2018-08-31 | 2019-08-30 | Isoquinoline-steroid conjugates and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535147A JP2021535147A (ja) | 2021-12-16 |
| JP2021535147A5 true JP2021535147A5 (enExample) | 2022-08-31 |
| JP7437384B2 JP7437384B2 (ja) | 2024-02-22 |
Family
ID=69639319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510761A Active JP7437384B2 (ja) | 2018-08-31 | 2019-08-30 | イソキノリンステロイド抱合体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11059789B2 (enExample) |
| EP (1) | EP3843736A4 (enExample) |
| JP (1) | JP7437384B2 (enExample) |
| KR (1) | KR20210053301A (enExample) |
| CN (1) | CN112638386A (enExample) |
| AU (2) | AU2019328590B2 (enExample) |
| BR (1) | BR112021003613A2 (enExample) |
| MX (1) | MX2021002380A (enExample) |
| SG (1) | SG11202101517PA (enExample) |
| WO (1) | WO2020047496A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7437384B2 (ja) | 2018-08-31 | 2024-02-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | イソキノリンステロイド抱合体およびその使用 |
| US12509469B2 (en) | 2019-08-07 | 2025-12-30 | Ripple Therapeutics Corporation | Compositions and methods for the treatment of pain and dependence disorders |
| US20230149387A1 (en) * | 2020-04-08 | 2023-05-18 | Aerie Pharmaceuticals, Inc. | Treatments |
| WO2021220061A2 (en) | 2020-05-01 | 2021-11-04 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
| JP2024516193A (ja) * | 2021-04-29 | 2024-04-12 | エアリー ファーマシューティカルズ インコーポレイテッド | 安定なイソキノリン－コルチコステロイドコンジュゲートおよびその使用 |
| EP4426712A4 (en) * | 2021-11-03 | 2026-04-08 | Ripple Therapeutics Corp | COMPOSITIONS SUITABLE FOR PROCESSING AND THEIR USE |
| CN115340472B (zh) * | 2022-09-19 | 2024-05-07 | 合肥工业大学 | 一种谷氨酸衍生物及其合成方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3193459A (en) * | 1955-07-01 | 1965-07-06 | Upjohn Co | Steroid hemisuccinate compositions and method for extemporaneous administration |
| US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| EP2109617A1 (en) * | 2007-02-05 | 2009-10-21 | Nicox S.A. | Nitric oxide releasing steroids |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (en) * | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| BR112015021388A2 (pt) * | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados esteroides de ciclosporina a |
| RU2015138891A (ru) * | 2013-03-08 | 2017-04-11 | Аллерган, Инк. | Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами |
| ES2852377T3 (es) * | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| EP3500251A4 (en) * | 2016-08-19 | 2020-04-08 | Aerie Pharmaceuticals, Inc. | BETA AMINO ISOCHINOLINYL AMIDE COMPOUNDS |
| JP7437384B2 (ja) | 2018-08-31 | 2024-02-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | イソキノリンステロイド抱合体およびその使用 |
-
2019
- 2019-08-30 JP JP2021510761A patent/JP7437384B2/ja active Active
- 2019-08-30 MX MX2021002380A patent/MX2021002380A/es unknown
- 2019-08-30 KR KR1020217008114A patent/KR20210053301A/ko not_active Abandoned
- 2019-08-30 CN CN201980056414.7A patent/CN112638386A/zh active Pending
- 2019-08-30 SG SG11202101517PA patent/SG11202101517PA/en unknown
- 2019-08-30 BR BR112021003613-0A patent/BR112021003613A2/pt not_active Application Discontinuation
- 2019-08-30 WO PCT/US2019/049195 patent/WO2020047496A1/en not_active Ceased
- 2019-08-30 AU AU2019328590A patent/AU2019328590B2/en not_active Ceased
- 2019-08-30 US US16/557,779 patent/US11059789B2/en active Active
- 2019-08-30 EP EP19853977.7A patent/EP3843736A4/en not_active Withdrawn
-
2021
- 2021-06-04 US US17/339,828 patent/US11691950B2/en active Active
-
2023
- 2023-07-12 AU AU2023204624A patent/AU2023204624A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535147A5 (enExample) | ||
| US11026900B2 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| JP2024133475A5 (enExample) | ||
| JP2020075939A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| JP2017510610A5 (enExample) | ||
| JP2021530453A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| JP2019515909A5 (enExample) | ||
| JP2023548055A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JPWO2020175629A5 (enExample) | ||
| CR20210043A (es) | Forma de dosificación farmacèutica administrable por vía oral con liberación modificada | |
| JP2023553253A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| JP2024543345A5 (enExample) | ||
| JP2018529747A5 (enExample) | ||
| JP2013507382A5 (enExample) | ||
| JP2021511352A5 (enExample) | ||
| JP2021525758A5 (enExample) | ||
| JP2022505184A5 (enExample) | ||
| JP2019513151A5 (enExample) |